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Purpose: Mutations of clarin 1 (CLRN1) cause Usher syndrome type 3 (USH3). To determine the effects of USH3
mutations on CLRN1 function, we examined the cellular distribution and stability of both normal and mutant CLRN1 in
vitro. We also searched for novel disease-causing mutations in a cohort of 59 unrelated Canadian and Finnish USH patients.
Methods: Mutation screening was performed by DNA sequencing. For the functional studies, wild-type (WT) and mutant
CLRN1 genes were expressed as hemagglutinin (HA) tagged fusion proteins by transient transfection of BHK-21 cells.
Subcellular localization of CLRN1-HA was examined by confocal microscopy. The N-glycosylation status of CLRN1
was studied by using the N-glycosidase F (PNGase F) enzyme and western blotting. Cycloheximide treatment was used
to assess the stability of CLRN1 protein.
Results: We found three previously reported pathogenic mutations, p.A123D, p.N48K, and p.Y176X, and a novel
sequence variant, p.L54P, from the studied USH patients. The WT HA-tagged CLRN1 was correctly trafficked to the
plasma membrane, whereas mutant CLRN1-HA proteins were mislocalized and retained in the endoplasmic reticulum.
PNGase F treatment of CLRN1-HA resulted in an electrophoretic mobility shift consistent with sugar residue cleavage
in WT and in all CLRN1 mutants except in p.N48K mutated CLRN1, in which the mutation abolishes the glycosylation
site. Inhibition of protein expression with cycloheximide indicated that WT CLRN1-HA remained stable. In contrast, the
CLRN1 mutants showed reduced stability.
Conclusions: WT CLRN1 is a glycoprotein localized to the plasma membrane in transfected BHK-21 cells. Mutant
CLRN1 proteins are mislocalized. We suggest that part of the pathogenesis of USH3 may be associated with defective
intracellular trafficking as well as decreased stability of mutant CLRN1 proteins.
Usher syndrome (USH) describes a group of autosomal
recessive diseases with bilateral sensorineural hearing loss
and  visual  impairment  phenotypically  similar  to  retinitis
pigmentosa  (RP)  [1-4].  Prevalence  of  USH  in  different
populations is estimated to range from 3.5 to 6.2 per 100,000,
thus making it the most frequent cause of combined deaf-
blindness worldwide [5]. The condition has been classified
into three clinical subtypes (USH1, USH2, and USH3), based
on the severity and progression of the hearing impairment,
presence or absence of vestibular dysfunction, and the age of
onset of RP [1]. This classification remains in clinical use,
although  recent  progress  on  the  molecular  genetics  and
clinical  research  of  USH  has  revealed  broad  genetic  and
clinical heterogeneity [3,6]. Atypical forms of USH have been
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identified  within  all  three  clinical  types,  and  there  is
considerable overlap of symptoms among the subtypes. A
distinguishing  feature  of  USH3  is  the  wide  spectrum  of
nonlinear progressive hearing impairment, which ranges from
a near normal to a severe audiometric phenotype [7]. USH3
patients may also have either normal or decreased vestibular
responses [8]. The rate of visual loss in USH3 is similar to
other  USH  subtypes  [9],  with  the  most  recent  analyses
suggesting that retinal degeneration in USH3 progresses more
rapidly than in USH2A [10,11]. The variable phenotype may
cause  USH3  to  be  under-diagnosed  and  it  may  be  more
prevalent than previously indicated [6].
To date, nine USH gene products have been identified:
the molecular motor myosin VIIa (USH1B) [12]; the cell
adhesion  proteins  cadherin  23  (USH1D)  [13]  and
protocadherin  15  (USH1F)  [14,15];  the  scaffold  proteins
harmonin (USH1C) [16], SANS (USH1G) [17], and whirlin
(USH2D)  [18];  the  G-protein-coupled  7-transmembrane
receptor  VLGR1b  (USH2C)  [19];  two  isoforms  of  the
extracellular matrix connected protein usherin (USH2A) [20,
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180621]; and the four-pass transmembrane domain protein clarin
1 (USH3) [22,23]. There is growing evidence suggesting that
these  proteins  form  a  network,  which  is  critical  for  the
development and maintenance of the sensorineural cells in the
inner ear and the retina [3,4,24-28].
Since the original identification of the causative gene for
USH3 [22], the gene’s structure has been refined. The newly
defined CLRN1 has three exons, encoding a 232 amino acid
protein [23,29]. Northern blot and reverse-transcription PCR
analyses indicate expression of different splice variants of
CLRN1 mRNA in several tissues including retina, cochlea,
brain, and thymus [22,23,29]. In situ hybridization analyses
demonstrate Clrn1 expression in mouse cochlear hair cells
and spiral ganglion cells as early as embryonic day (E) 16.5
[23,30]. The CLRN1 protein is thought to be expressed in
mouse cochlea transiently from E18 to postnatal day (P) 6 in
basal  parts  of  the  hair  cells,  whereas  in  apical  parts
(stereocilia) the CLRN1 expression is lost already at P1. In
adult  mouse  retina  CLRN1  localizes  to  inner  segments,
connecting cilia and ribbon synapses. The function of CLRN1
remains unknown; however, the spatiotemporal expression
pattern of CLRN1 in hair cells implicates protein involvement
in  synaptic  maturation  [31].  Structural  and  sequence
homology with the synaptic protein stargazin suggest a role
for CLRN1 in the plasma membranes surrounding ribbon
synapses of the inner ear and retina [23]. In cell culture studies
CLRN1 forms microdomains in the plasma membrane, affects
F-actin  organization  and  induces  lamellipodia  formation,
implicating  CLRN1  involvement  in  actin  cytoskeleton
regulation  [28].  This  hypothesis  is  supported  by  the
observation that Clrn1 knockout mouse F-actin-rich hair cell
stereocilia  are  disorganized  [28,30].  In  mouse  hair  cell
cultures, however, CLRN1 associates with tubulin and not
with  actin,  and  localizes  to  post-transgolgi  vesicles,
suggesting a potential function for CLRN1 in vesicle transport
[31].
To date, USH3 has been described as the rarest of the
USH  types  worldwide.  The  availability  of  molecular
diagnosis is increasing the number of USH3 cases identified.
Interestingly,  in  unrelated  Ashkenazi  Jewish  and  Finnish
populations, USH3 comprises 40% of all the USH cases,
suggesting multiple founder effects [9,32]. Among Ashkenazi
Jews of European and North American descent, a c.144T>G
mutation is causative of the majority of the USH3 cases. This
mutation  causes  a  substitution  of  asparagine  to  lysine
(p.N48K), and removes the single N-glycosylation consensus
site on the CLRN1 protein [29]. The most common mutation
in Finland is c.528T>G, which is predicted to generate a
premature termination of the CLRN1 polypeptide (p.Y176X).
Eleven other CLRN1 mutations have been documented in
USH3 patients around the world. These mutations include c.
359T>A (p.M120K) found in four Finnish patients, c.368C>A
(p.A123D) found in one French Canadian patient, c.449T>C
(p.L150P)  found  in  one  Ashkenazi  Jewish  patient,  and  c.
459_461del (p.I153_L154delinsM) identified in two Italian
patients. The other seven known CLRN1 mutations have been
found  in  either  single  patients  or  isolated  families  with
predominantly European ancestry [8,11,18,22,23,29,32-34].
In this study, we sequenced the coding region of CLRN1
in  59  USH  patients  who  had  no  known  disease-causing
mutations. Furthermore, we examined intracellular targeting,
stability, and N-glycosylation of the aforementioned mutants
in addition to WT CLRN1 using a transient transfection assay
in BHK-21 cells.
METHODS
Subjects:  Patients  diagnosed  with  USH  were  recruited
through the Ocular Genetics Clinic at The Hospital for Sick
Children  in  Toronto,  Ontario,  Canada  and  from  Helsinki
University  Eye  Hospital,  Helsinki,  Finland.  This  study
followed the tenets of the Declaration of Helsinki.
Clinical examinations: The diagnosis of USH was based on
comprehensive  ophthalmological  and  audiological
examinations including Snellen visual acuity, biomicroscopy
and  fundus  examinations,  Goldmann  visual  field  tests,
electroretinograms,  and  pure  tone  audiograms.  When
possible, optical coherent tomography (OCT) was performed.
Mutation analysis: DNA samples of 40 unrelated Canadian
USH patients without previously known mutations and 19
USH patients diagnosed in Finland after 2001 were sequenced
for CLRN1 mutation identification. Patients’ genomic DNA
was extracted either from fresh or frozen whole blood samples
with  Puregene™  Genomic  DNA  Purification  Kit  (Gentra
Systems, MN) or from saliva with Oragene™ kits (DNA
Genotek Inc., Ontario, Canada). A total of 90 Centre d’Etude
du Polymorphisme Humain (CEPH) samples were used as
controls for assessing the pathogenicity of the novel change
found in this study from a Canadian USH patient. The three
exons  and  the  exon-intron  boundaries  of  the  main  splice
variant of CLRN1 gene (GenBank accession NM_174878)
were screened for mutations by genomic sequencing. The
primers used for sequencing were: exon 0 sense 5′-CAG AAA
AGG AGA AAA GCC AAG-3′; exon 0 antisense 5′-CTG
GGA AGA GTC TGC CTA AA-3′; exon 2 sense 5′-TCA
GAA GGA TTT TAG TGA TGT TTG A-3′; exon 2 antisense
5′-TCT TTT TGA CAT ATT GAA AAG CAC A-3′; exon 3
sense 5′-CCC TCT TCC CTG TCC CTT AC –3′; exon 3
antisense 5′- CCA CAT CTA AAA GTG ACC AAA GC-3′.
The  amplification  conditions  were  95  °C  for  5  min
(denaturation), then 30 cycles of 95 °C for 45 s, 60 °C (exon
2) or 55 °C (exons 0 and 3) for 45 s, 72 °C for 45 s, followed
by a final extension of 10 min at 72 °C. PCR products were
purified  with  Exo-SAP  (USB,  Cleveland,  OH)  and  then
sequenced with an ABI2720 Automatic DNA sequencer using
the ABI PRISM BigDye® Terminator v3.1 Cycle Sequencing
Kit (Applied Biosystems, Foster City, CA). The sequences
were compared to the known  CLRN1 main splice variant
sequence (NM_174878).
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CLRN1 construct was cloned into the phCMV3 Xi cloning
vector (Gene Therapy Systems, Inc., San Diego, CA) with C-
terminal  hemagglutinin  epitope  YPYDVPDYA  (HA-tag)
from the influenza virus A as recently described [28]. The
mutant  cDNA  constructs  representing  mutations/sequence
alterations p.N48K, p.L54P, p.M120K, p.A123D, p.L150P,
and p.I153_L154delinsM were generated by the QuikChange
site-directed  in  vitro  mutagenesis  kit,  according  to  the
manufacturer’s  protocols  (Stratagene,  La  Jolla,  CA).  All
coding regions of the constructs were sequence verified.
Cell  culture  and  transfections:  BHK-21  cells  (CCL-10,
ATCC) were cultured in Glasgow minimal essential medium
(GMEM, Sigma-Aldrich, St. Louis, MO) supplemented with
10%  fetal  calf  serum  (FCS;  PromoCell™,  Heidelberg,
Germany),  Gibco™  GlutaMAX™  supplement  (100x,  L-
alanyl-L-glutamine, Invitrogen), 5% tryptose phosphate broth
solution (Sigma-Aldrich), and penicillin-streptomycin (100x,
Sigma-Aldrich, Germany). For transfection, cells were seeded
on  13  mm  coverslips  (Menzel-Gläser,  Braunschweig,
Germany) in six well plates (Nunc™, Denmark) at a density
of 2×105 cells per well 20 h before transfection. Transfection
was performed with the FuGENE 6 Transfection Reagent
(Roche  Diagnostics,  Indianapolis,  IN)  following  the
guidelines supplied by the manufacturer. Experiments were
performed 24 or 48 h post transfection.
Immunofluorescence imaging: WT and mutant CLRN1-HA
transfected cells were fixed with 4% paraformaldehyde (PFA;
pH 7.5) for 15 min before immunofluorescence staining. For
stability analyses, protein synthesis was stopped by adding
50  µg/ml  cycloheximide  (Sigma-Aldrich)  and  incubating
BHK-21 cells in it before fixation (as above). After fixation,
BHK-21  cells  were  permeabilized  for  20  min  with  0.2%
saponin (Sigma-Aldrich) in phosphate buffered saline (PBS;
137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, and 1.5 mM
KH2PO4   in     distilled     water,     pH   7.4)      containing   
Thereafter,   the   cells   were    incubated    for   45    min
with   a   1:700   dilution   of   monoclonal  anti-HA
antibody (HA.11, MMS-101R; Covance, Berkeley, CA) and
either with a 1:50 dilution of plasma membrane antibody to
sodium  potassium  ATPase  (ab7671;  Abcam,  Cambridge,
UK), or a 1:200 dilution of an ER antibody to protein disulfide
isomerase (PDI, spa-891; Stressgen, Victoria, Canada). Cy2-
and  Cy3–conjugated  secondary  antibodies  (Jackson
ImmunoResearch, West Grove, PA) were used to visualize
the primary antibodies. The cells were mounted with Gel/
Mount (Biomeda, Foster City, CA) and analyzed with a Leica
DMR confocal microscope with TCS NT software, or a Zeiss
Axioplan 2 microscope with AxioVision 3.1 software.
Western  blot  and  deglycosylation  analyses:  Transfected
BHK-21 cells were harvested from six-well plates for western
blot analysis by scraping in ice-cold PBS supplemented with
protease  inhibitors  (Complete;  Roche  Diagnostics).  Cells
were  collected  by  centrifugation.  These  were  lysed  with
200 µl glycoprotein denaturing buffer (0.5% SDS, 40 mM
DTT; New England Biolabs, Ipswich, MA). Cells were further
homogenized by passage through a 21 gauge needle. Next,
2 µl of 10% NP-40 and 2 µl of 50 mM sodium phosphate
buffer, pH 7.5 (G7 Reaction Buffer) was added to the 15 µl
sample of the cell homogenate. Samples for deglycosylation
studies  were  treated  with  0.5  µl  (500  units/µl)  of  N-
glycosidase F (PNGase F; New England Biolabs) enzyme for
2 h at 37 °C. Samples were separated on a 12% SDS–PAGE
gel and transferred to a Trans-Blot® nitrocellulose membrane
(Bio-Rad, Hercules, CA). The membrane was immunostained
with  a  1:1,000  dilution  of  monoclonal  anti-HA  antibody
Figure 1. Sequence conservation around
the  p.L54P  and  p.A123D  changes.
Amino acids conserved in evolution are
marked  in  bold,  and  mutations  are
marked  with  red.  Mutations  are  also
marked with an asterisk. Abbreviations:
Homo  sapiens  (HS),  Pan  troglodytes
(Pt),  Bos  taurus  (Bt),  Mus  musculus
(Mm), Gallus gallus (Gg), Danio rerio
(Dr).
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0.5% bovine    serum    albumin    (BSA;    Sigma-Aldrich).(Covance) and a 1:1,000 dilution of polyclonal rabbit anti-
mouse IgG conjugated to HRP (DakoCytomation, Glostrup,
Denmark).  Bands  were  visualized  by  SuperSignal®  West
Pico Chemiluminescent Substrate (Pierce, Rockford, IL) and
captured on X-ray film (Kodak Biomax MR Film, Sigma-
Aldrich).
Bioinformatics:  The  theoretical  molecular  weights  of
CLRN1-HA polypeptides were calculated with the Protein
Molecular Weight Program [35]. The TMHMM2.0 program
was used for prediction of membrane spanning regions [36].
RESULTS
Sequence  alterations  in  CLRN1:  The  sequencing  of  the
CLRN1 coding region from the 40 Canadian USH patients
revealed  two  previously  published  and  one  novel  CLRN1
sequence  alteration.  The  previously  unreported  c.161T>C
transition, found in heterozygous form, predicts a p.L54P
change. We did not find another CLRN1 sequence alteration
in this patient, but the changed amino acid leucine is conserved
in evolution (Figure 1). Thus, the pathogenic nature of this
alteration was investigated further. A transition mutation c.
368C>A  predicting  a  p.A123D  change  was  identified  in
homozygous  form  in  a  Canadian  patient  originating  from
Dominica. The mutation changes another highly conserved
amino acid alanine to aspartic acid (Figure 1). This change has
previously been reported in a French Canadian patient [34]
and  is  very  likely  a  mutation  causing  USH3.  Neither  c.
161T>C nor c.368C>A were found from the 90 CEPH control
samples  nor  the  19  Finnish  patients  we  sequenced.  The
Ashkenazi  Jewish  mutation  (p.N48K)  was  detected  in  a
Canadian USH patient in homozygous form, and in a Finnish
patient  in  heterozygous  form  with  the  Finnish  founder
mutation p.Y176X. The mutations identified in the present
study, as well as CLRN1 disease-causing mutations identified
in patients in other studies (Table 1), are summarized on a
schematic presentation of the predicted CLRN1 structure in
Figure 2.
Clinical findings in the patients whose mutations were found
in  this  study:  The  Canadian  patient  with  a  homozygous
p.N48K mutation was diagnosed with RP and hearing loss in
his late teens. At age 54, he had 5 degree visual fields with the
III4e stimulus. His best-corrected visual acuities were 20/30
OU (following cataract surgery). He had a mild to moderate,
downsloping sensorineural hearing loss and poor balance.
OCT showed small cystic macular changes at age 52 (Figure
3D). The Canadian patient with the homozygous p.A123D
Figure 2. Predicted membrane topology
of  CLRN1.  Disease-associated
mutations  are  marked;  the  frameshift
and  nonsense  mutations  are  marked
with  red  amino  acids,  missense
mutations are marked with blue amino
acids,  and  the  deleted  amino  acids
replaced by an insertion are marked with
green.  Transmembrane  regions  (1–4)
were  predicted  using  a  TMHMM2.0
program [36]. The mutations studied in
this article are marked with red.
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1811mutation had progressive sensorineural hearing loss that was
first noted at age 7. By age 32, her hearing loss was moderately
severe,  sloping  to  profound  hearing  loss.  She  noticed
symptoms of RP at age 25, when her ERG was nonrecordable.
At 36, her visual fields were 12 degrees measured with the
III4e stimulus, and the best-corrected visual acuities were
20/25 OU. On OCT, there was a schisis-like change in her
macula  (Figure  3C).  Fundus  changes  were  otherwise
characteristic  of  RP.  The  Finnish  p.N48K/p.Y176X
compound  heterozygous  patient  was  diagnosed  with
sensorineural hearing loss at age 7; testing revealed a U-
shaped audiogram. At age 8, his visual acuity was 20/20 OU.
He had slight mottling of the pigment in his peripheral fundi,
and his visual fields, measured with the V4e standard light,
were normal. His full-field ERGs were nonrecordable. On
OCT examination, the foveal thickness looked fairly normal
but there was thinning of the retina outside the central fovea
(Figure 3B).
Cellular localization of CLRN1-HA: To determine the cellular
localization of the CLRN1 protein, we cloned the transcript of
CLRN1 (NM_174878) into a HA-tagged phCMV mammalian
expression vector. We generated mutant cDNA constructs by
the QuikChange site-directed mutagenesis kit. The mutant and
WT proteins were transiently expressed in BHK-21 cells.
Their refined cellular localizations were visualized by anti-
HA, anti-ER (protein disulfide isomerase), and anti-plasma
membrane  (sodium  potassium  ATPase)  antibodies,  using
confocal immunofluorescence microscopy. WT CLRN1 was
observed  throughout  the  plasma  membrane  of  transfected
cells (Figure 4A-C), but it also showed partial colocalization
with  the  ER  marker  (Figure  4D-F),  indicating  its  normal
processing  through  the  ER  to  the  plasma  membrane.  In
contrast,  all  known  mutant  proteins  analyzed  colocalized
almost exclusively within the ER, suggesting that they are
retained therein and prevented from targeting to the plasma
membrane (Figure 5). The novel sequence alteration p.L54P
localized to the plasma membrane (Figure 6A-C) similar to
WT CLRN1 (Figure 6D-F), and unlike the known mutation
p.N48K  (Figure  6G-I).  The  biologic  significance  of  the
p.L54P alteration found in a patient in heterozygous form
remains thus unclear.
Stability of WT and mutant CLRN1-HA polypeptides: We
studied  the  stability  of  the  WT  and  mutant  CLRN1-HA
proteins  by  interrupting  protein  synthesis  in  transfected
BHK-21 cells by cycloheximide treatment and examining
how  much  protein  remained  after  4  h.  WT  CLRN1,  the
p.I153_L154delinsM and p.M120K mutants could still be
detected, while the p.N48K, p.A123D and p.L150P mutants
were almost completely absent (Figure 7). ER marker served
as  a  control.  Stability  of  the  marker  was  unaltered  by
cycloheximide treatment (data not shown).
CLRN1-HA  forms  multimers:  Based  on  computational
predictions, the molecular weight of WT CLRN1-HA with no
modifications is 26.81 kDa [35]. WT CLRN1-HA has a single
putative N-glycosylation site at amino acid position 48 [23,
28]. To study CLRN1 glycosylation in vitro, we treated HA-
tagged  WT  CLRN1  and  p.N48K  mutated  CLRN1
polypeptides  produced  in  transiently  transfected  BHK-21
cells with PNGase F, an enzyme that removes all N-linked
oligosaccharide side chains from glycoproteins. Western blot
analysis of WT CLRN1-HA showed several bands ranging
from 23 up to 98 kDa (Figure 8, lane 1). After PNGase F
treatment,  two  major  bands  at  27  kDa  and  48  kDa  were
observed (Figure 8, lane 2). In contrast, PNGase F treatment
Figure 4. Cellular localization of WT
CLRN1-HA  protein  in  transfected
BHK-21 cells. In panels B and E the
cells  were  immunostained  with  HA
antibody (red). In panel A the cells were
immunostained  with  a  plasma
membrane specific antibody (green) and
in panel D with ER specific antibody
(green). The right-most panels (C and
F) show the overlay of both CLRN1-HA
and  the  organelle-specific  double
staining.  Yellow-orange  staining
indicates an overlap of the CLRN1-HA
protein  (red)  and  subcellular  markers
(green).  Cells  were  viewed  with  a
confocal  immunofluorescence
microscope,  magnification  63×.  Scale
bar represents 10 μm.
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1812Figure  5.  Cellular  localization  of  the  disease-causing  mutant  CLRN1-HA  polypeptides.  The  transfected  BHK-21  cells  were  double
immunostained with HA antibody (red) in panels B, E, H, K, and N showing the localization of mutant CLRN1-HA. In panels A, D, G, J, and
M the cells were stained with the ER marker (green). The right-most panels C, F, I, L, and O show the overlay of the mutant CLRN1- HA
staining (red) and ER-specific staining (green). Yellow-orange staining indicates colocalization of these stainings. Cells were viewed with a
confocal immunofluorescence microscope. Scale bar represents 10 µm.
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1813had no effect on p.N48K samples: the same 23, 27, and 48 kDa
bands were observed in both PNGase F treated and untreated
samples (Figure 8, lanes 3 and 4). These results confirm that
CLRN1 is a glycoprotein like previously reported and that the
p.N48K mutation disrupts the protein’s single glycosylation
site [28]. The presence of a 48 kDa band suggests that CLRN1
has a tendency to form dimers. The other studied mutations,
p.M120K,  p.A123D,  p.L150P,  and  p.I153_L154delinsM,
were glycosylated (Figure 8, lanes 7–16), and clearly showed
decreased molecular weights following PNGase F treatment.
Their glycoform patterns were, however, different from that
of the WT, probably reflecting their retention in the ER.
DISCUSSION
A total of 13 CLRN1 mutations in more than 100 USH3
patients  have  been  reported  worldwide.  The  two  most
common single mutations are the founder mutations p.Y176X
in the Finnish population, and the p.N48K mutation among
Ashkenazi  Jews  [22,23,32].  The  remaining  11  reported
CLRN1  mutations  occur  in  single,  often  consanguineous
families,  and  are  not  known  to  be  widely  distributed.
Therefore, it is not surprising that we found one p.N48K
homozygote  among  40  Canadian  USH  patients,  and  one
compound p.Y176X/p.N48K heterozygote in Finland. The
p.A123D  mutation  was  found  in  a  Canadian  patient
originating from Dominica. Interestingly, the same mutation
has previously been reported in a French Canadian USH1
patient [34].
Clinical  studies  of  USH3  patients  have  failed  to
determine  any  clear-cut  genotype-phenotype  correlations
while broad intrafamilial and mutational variety in the onset,
progression, and severity of symptoms are reported among the
largest patient groups, Ashkenazi Jews [11,32], and Finns [7,
9,10]. The homozygous p.A123D patient, the homozygous
p.N48K patient, and the combined heterozygous p.Y176X/
p.N48K  patient  reported  in  this  study  had  what  can  be
considered typical USH3 phenotypes.
The  CLRN1  gene  is  predicted  to  encode  a  four-pass
transmembrane domain protein [23]. Our results are in line
with the previous observations that full-length WT CLRN1 is
sorted  to  specific  membrane  compartments  or  to  the  cell
surface  [28,31].  Interestingly,  molecular  masses  of  the
CLRN1-HA  polypeptides  observed  on  our  western  blots
suggest that CLRN1 may form dimers and even higher order
Figure  6.  Cellular  localization  of  the
p.L54P, p.N48K and WT CLRN1-HA
polypeptides. The transfected BHK-21
cells  were  immunostained  with  HA
antibody (red) showing the localization
of  WT  CLRN1-HA  (E),  the  novel
sequence  alteration  p.L54P  mutated
CLRN1-HA (B) and the known disease-
causing  p.N48K  mutated  CLRN1-HA
(H).  The  same  cells  were
immunostained with plasma membrane
–specific antibody (green) in panels A,
D, and G. Double-staining shows that
WT  CLRN1-HA  (F)  and  the  p.L54P
mutated  CLRN1-HA  (C)  colocalize
(yellow)  with  the  plasma  membrane
marker  whereas  the  known  mutation
p.N48K (I) does not colocalize with the
plasma membrane marker. Cells were
viewed  with  a  confocal
immunofluorescence microscope. Scale
bar represents 10 µm.
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1814Figure 7. Stability of WT and mutant CLRN1-HA polypeptides in transfected BHK-21 cells. Cells were transiently transfected either with
WT or mutant CLRN1-HA cDNAs. At 48 h posttransfection protein synthesis was stopped by incubating the cells for 4 h in the presence of
50 µg/ml of cycloheximide. Cells were viewed with a Zeiss Axioplan 2 fluorescence microscope. The scale bar represents 50 µm.
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1815complexes. The function of the protein still remains unclear.
The eight other known USH gene products are hypothesized
to form an USH interactome with a role in the molecular
transport in the photoreceptor connecting cilium, and in the
development and function of cochlear hair cells [3,26-28].
The  possible  role  of  CLRN1  in  the  USH  interactome,
however, remains unclear.
Half of the known CLRN1 mutations result in a premature
termination codon and are likely to lead to nonfunctional
proteins. Alternatively, the mutant mRNAs may be degraded
by  the  nonsense-mediated  decay  pathway  [37].  To  assess
pathogenic  mechanisms  of  nontruncating  mutations,  we
studied consequences of four missense mutations (p.N48K,
p.M120K,  p.A123D,  and  p.L150P),  and  that  of  the
p.I153_L154delinsM  mutation  by  expressing  HA-tagged
mutant  cDNAs  in  BHK-21  cells.  We  showed  that  all  the
mutant CLRN1 proteins studied are retained in the ER and not
trafficked to the plasma membrane. This is in line with the fact
that missorting and mistrafficking of membrane proteins is a
well-described mechanism of cell degeneration [38,39].
We also studied the stability of WT and mutant proteins
and found that all studied mutants were less stable than WT
CLRN1-HA. The p.N48K, p.A123D and p.L150P mutants
degraded  more  rapidly  than  p.M120K  and
p.I153_L154delinsM.  A  recent  study  with  HEK-293  cells
shows  that  disruption  of  glycosylation  site  by  p.N48K
mutation as well as removal of the N-linked sugar residue
from  the  WT-CLRN1  both  cause  protein  degradation,
suggesting that the incorrect glycosylation is the cause for
p.N48K mutated CLRN1 degradation [28]. Our study showed
that  mutations  other  than  p.N48K  are  glycosylated,  yet
unstable. Therefore, it seems that glycosylation is not the sole
determining  factor  for  destabilization  of  mutated  CLRN1
proteins in general. The accumulation of mutated proteins that
cells  inefficiently  degrade  may  cause  ER  stress  [40,41].
Retained as well as improperly processed mutant CLRN1
polypeptides are likely to cause ER stress, which in turn may
trigger apoptosis in retinal and cochlear sensory epithelia. In
a previous study, we showed that apoptosis is a probable
pathogenic mechanism in USH3, as apoptotic cochlear cell
destruction  resulted  from  adeno-associated  viral  vectored
ribozyme-initiated knockdown of Clrn1 in the mouse cochlea
[42].
In  summary,  our  results  showed  that  CLRN1  is  a
glycoprotein that forms multimers in plasma membranes of
cultured  cells.  Further,  we  showed  that  instability  and
defective routing of mutant polypeptides are critical aspects
of the etiology of USH3.
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